Apollomics Financials
| APLM Stock | 8.50 0.44 4.92% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.22 | 3.39 |
|
|
Investors should never underestimate Apollomics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Apollomics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Apollomics Class A.
Net Income |
|
Apollomics | Select Account or Indicator |
Understanding current and past Apollomics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Apollomics' financial statements are interrelated, with each one affecting the others. For example, an increase in Apollomics' assets may result in an increase in income on the income statement.
Apollomics Stock Summary
Apollomics competes with Inter Parfums, Toro, Beauty Health, Fomento Economico, and Edgewell Personal. Apollomics is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 57778T106 G0411D107 G0411D123 |
| Location | California; U.S.A |
| Business Address | 989 East Hillsdale |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.apollomicsinc.com |
| Phone | 650 209 4055 |
Apollomics Key Financial Ratios
| Return On Equity | -1.49 | ||||
| Operating Margin | (14.32) % | ||||
| Price To Sales | 4.69 X | ||||
| Revenue | 821 K | ||||
| EBITDA | (171.75 M) |
Apollomics Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Apollomics's current stock value. Our valuation model uses many indicators to compare Apollomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Apollomics competition to find correlations between indicators driving Apollomics's intrinsic value. More Info.Apollomics Class A is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . At this time, Apollomics' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Apollomics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Apollomics Class A Systematic Risk
Apollomics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Apollomics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Apollomics Class A correlated with the market. If Beta is less than 0 Apollomics generally moves in the opposite direction as compared to the market. If Apollomics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Apollomics Class A is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Apollomics is generally in the same direction as the market. If Beta > 1 Apollomics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Apollomics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Apollomics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Apollomics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Apollomics January 31, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Apollomics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Apollomics Class A. We use our internally-developed statistical techniques to arrive at the intrinsic value of Apollomics Class A based on widely used predictive technical indicators. In general, we focus on analyzing Apollomics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Apollomics's daily price indicators and compare them against related drivers.
| Downside Deviation | 9.25 | |||
| Information Ratio | 2.0E-4 | |||
| Maximum Drawdown | 134.75 | |||
| Value At Risk | (15.46) | |||
| Potential Upside | 18.55 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apollomics Class A. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apollomics. If investors know Apollomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apollomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share | Quarterly Revenue Growth 2.623 | Return On Assets | Return On Equity |
The market value of Apollomics Class A is measured differently than its book value, which is the value of Apollomics that is recorded on the company's balance sheet. Investors also form their own opinion of Apollomics' value that differs from its market value or its book value, called intrinsic value, which is Apollomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apollomics' market value can be influenced by many factors that don't directly affect Apollomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apollomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apollomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apollomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.